CGEN

Compugen Ltd

1.98

Oct 30 • 3:59 PM ET -0.06 (-2.94%)

1.98

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Israel Micro NASD

Peers: MGNX ADAG AGEN ALXO CMPX CUE RCUS ABCL AZN GILD

| Held by: SPDW AVDV GWX QQQS AVSD AESG AESB

Scroll to Statements

Index	-
Market Cap	187.56M
Enterprise Value	65.28M
Income	35.19M
Sales	74.00M
Book/sh	0.94
Cash/sh	1.32
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	75
IPO	Aug 11, 2000

P/E	5.35
Forward P/E	-
PEG	-
P/S	2.53
P/B	2.11
P/C	1.50
P/FCF	-
EV/EBITDA	-
EV/Sales	0.88
Quick Ratio	5.72
Current Ratio	5.72
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	0.37
EPS next Y	-0.28
EPS next Q	-0.08
EPS this Y	-173.68%
EPS next Y	1.43%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	113.28% 105.20%
EPS Y/Y TTM	277.28%
Sales Y/Y TTM	234.18%
EPS Q/Q	5.73%
Sales Q/Q	107.00%
Earnings	Nov 09 BMO
EPS/Sales Surpr.	12.50% 102.55%

Insider Own	0.37%
Insider Trans	-0.53%
Inst Own	15.10%
Inst Trans	-0.04%
ROA	28.74%
ROE	50.64%
ROIC	38.61%
Gross Margin	86.89%
Oper. Margin	40.94%
Profit Margin	47.55%
SMA20	-3.47%
SMA50	-14.78%
SMA200	-13.79%
Trades

Shs Outstand	94.72M
Shs Float	94.37M
Short Float	2.67%
Short Ratio	9.95
Short Interest	2.52M
52W High	3.23 -38.79%
52W Low	1.43 38.46%
Volatility	4.33% 5.10%
ATR (14)	0.10
RSI (14)	41.26
Beta	2.84
Rel Volume	1.01
Avg Volume	252.67K
Volume	255,462

Perf Week	2.06%
Perf Month	-15.38%
Perf Quarter	-16.81%
Perf Half Y	-26.94%
Perf YTD	29.41%
Perf Year	20.00%
Perf 3Y	189.05%
Perf 5Y	-69.49%
Perf 10Y	-65.26%
Recom	1.00
Target Price	4.60
Prev Close	2.04
Price	1.98
Change %	-2.94%

Consensus

Strong Buy

Avg. Price Target

$4.60

Implied Upside

+132.3%

Analysts12incl. previous ratings

Rating Distribution11 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 07, 2026	Initiated	LLake Street	Buy	$6	+203.0%
Jan 07, 2026	Initiated	HH.C. Wainwright	Buy	$4	+102.0%
Jan 13, 2025	Initiated	OOppenheimer	Outperform	$4	+102.0%
Aug 05, 2022	Downgrade	JJefferies	Buy → Hold	$2	+1.0%
May 26, 2020	Resumed	JJMP Securities	Mkt Outperform	$18	+809.1%
May 13, 2020	Initiated	SStifel	Buy	$19	+859.6%
May 07, 2020	Initiated	SSVB Leerink	Outperform
Apr 22, 2020	Initiated	RROTH Capital	Buy	$28	+1,314.1%
Mar 24, 2020	Initiated	SSunTrust	Buy	$16	+708.1%
Jan 16, 2020	Initiated	CCantor Fitzgerald	Overweight	$10	+405.1%
Mar 29, 2018	Initiated	OOppenheimer	Outperform
Feb 01, 2016	Resumed	OOppenheimer	Outperform
Oct 15, 2015	Initiated	FFBR Capital	Outperform	$14	+607.1%
Apr 23, 2015	Resumed	JJefferies	Buy	$11	+455.6%
Apr 21, 2015	Initiated	OOppenheimer	Outperform	$11	+455.6%
Feb 07, 2014	Initiated	MMLV & Co	Buy	$14	+607.1%
Dec 28, 2009	Reiterated	CCantor Fitzgerald	Buy	$5 → $12	+506.1%
Jul 29, 2009	Initiated	CCantor Fitzgerald	Buy	$6.50	+228.3%

Oct-26-26 07:00AM	Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 (PR Newswire)
Oct-06-26 07:00AM	Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference (PR Newswire)
Sep-22-26 07:00AM	Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen Platform Update on October 5, 2026 (PR Newswire)
Sep-08-26 07:00AM	Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Aug-26-26 07:00AM	TROPION-Urothelial04 Phase 3 Trial of Datroway Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer (Business Wire)
09:01PM	Loading…
Aug-05-26 09:01PM	Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... (GuruFocus.com)
Aug-03-26 07:03AM	Compugen: Q2 Earnings Snapshot (Associated Press)
07:00AM	Compugen Reports Second Quarter 2026 Results (PR Newswire)
Jul-31-26 09:20AM	Earnings To Watch: Compugen Ltd (CGEN) Reports Q2 2026 Result (GuruFocus.com)
Jul-21-26 07:00AM	Compugen to Participate in BTIG Biotechnology Conference 2026 (PR Newswire) +6.41%
Jul-20-26 07:00AM	Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 (PR Newswire)
Jun-18-26 07:00AM	Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress (PR Newswire)
Jun-11-26 07:00AM	Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 (PR Newswire)
Jun-08-26 07:00AM	Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development (PR Newswire)
May-25-26 09:01PM	Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
08:35AM	Loading…
May-18-26 08:35AM	Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) (InvestorsHub)
07:58AM	Compugen: Q1 Earnings Snapshot (Associated Press)
07:00AM	Compugen Reports First Quarter 2026 Results (PR Newswire)
May-12-26 07:00AM	Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum (PR Newswire)
May-04-26 07:00AM	Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026 (PR Newswire)
Apr-09-26 07:00AM	Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference (PR Newswire) +8.30%
Mar-03-26 08:03PM	Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -11.11% +7.00%
Mar-02-26 08:15AM	Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates (Zacks) +24.31%
07:17AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Fourth Quarter and Full Year 2025 Results (PR Newswire)
Feb-27-26 07:22AM	Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-26-26 09:55AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-25-26 07:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates (Zacks)
Feb-19-26 05:35PM	Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.29%
07:00AM	Compugen to Participate in Upcoming Investor Conferences (PR Newswire)
07:00AM	Loading…
Feb-17-26 07:00AM	Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 (PR Newswire)
Feb-12-26 07:00AM	Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors (PR Newswire)
Dec-17-25 07:00AM	Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million (PR Newswire)
Nov-12-25 10:01AM	Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-10-25 08:15AM	Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:16AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2025 Results (PR Newswire)
Nov-07-25 07:24AM	Compugen Ltd (CGEN) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-06-25 06:55PM	Certara, Inc. (CERT) Q3 Earnings Surpass Estimates (Zacks)
Nov-04-25 07:00AM	Compugen to Participate in Stifel 2025 Healthcare Conference (PR Newswire) -6.94%
Nov-03-25 05:15PM	Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 07:00AM	Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 (PR Newswire)
Oct-13-25 07:00AM	Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 (PR Newswire) +21.08%
Oct-06-25 07:00AM	Compugen to Present at SITC 2025 (PR Newswire) +9.82%
Sep-08-25 07:00AM	Compugen to Present Research at the Single Cell Genomics 2025 Conference (PR Newswire)
Aug-28-25 07:00AM	Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-06-25 08:20AM	Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Second Quarter 2025 Results (PR Newswire)
Jul-28-25 07:00AM	Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 (PR Newswire)
Jul-23-25 07:00AM	Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 (PR Newswire)
Jul-21-25 07:00AM	Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer (PR Newswire)
Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
10:38AM	XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? (Zacks)
08:54AM	Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
07:50AM	Graham (GHM) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
07:31AM	GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
Jun-17-25 11:10AM	Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? (Zacks)
07:38AM	EchoStar (SATS) Moves 49.1% Higher: Will This Strength Last? (Zacks)
Jun-12-25 07:00AM	Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences (PR Newswire)
May-20-25 03:03AM	Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline (GuruFocus.com)
May-19-25 11:55AM	Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
10:53AM	Compugen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports First Quarter 2025 Results (PR Newswire)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-14-25 06:35PM	Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 07:00AM	Compugen Announces Leadership Transitions Effective September 2025 (PR Newswire)
May-12-25 05:25PM	Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates (Zacks)
May-08-25 05:35PM	McKesson (MCK) Tops Q4 Earnings Estimates (Zacks)
May-05-25 07:00AM	Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 (PR Newswire) -7.43%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-26-25 07:00AM	Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 (PR Newswire)
Mar-23-25 08:29AM	Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-05-25 02:04AM	Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) +7.74%
Mar-04-25 08:15AM	Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.18%
08:15AM	Compugen Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
07:22AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	/C O R R E C T I O N -- Compugen Ltd./ (PR Newswire)
Mar-03-25 07:00AM	Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference (PR Newswire) -5.73%
Feb-26-25 07:00AM	Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen with Ultima Genomics' Single Cell Genomics Sequencing Technology (PR Newswire)
Feb-18-25 07:00AM	Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 (PR Newswire)
Feb-04-25 07:00AM	Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-08-25 07:00AM	Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors (PR Newswire)
Nov-27-24 07:00AM	Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies (PR Newswire) +5.92%
Nov-13-24 02:08AM	Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... (GuruFocus.com)
Nov-12-24 11:05AM	Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates (Zacks) -8.05%
09:56AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2024 Results (PR Newswire)
Nov-11-24 07:00AM	Compugen to Participate in Stifel 2024 Healthcare Conference (PR Newswire)
Nov-05-24 09:00AM	Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 (PR Newswire)
Oct-29-24 07:00AM	Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (PR Newswire)
Oct-07-24 07:00AM	Compugen to Present New Clinical Data at SITC 2024 (PR Newswire)
Sep-11-24 12:00PM	Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-09-24 07:00AM	Compugen to Present at Single Cell Genomics 2024 Conference (PR Newswire) +8.20%
Aug-29-24 07:00AM	Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +6.84%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levine Zurit	SVP, Business Development	Jul 09 '26	Option Exercise	0.83	1,875	1,555	31,250	Jul 13 04:01 PM
Levine Zurit	SVP, Business Development	Jul 09 '26	Sale	2.50	1,875	4,688	29,375	Jul 13 04:01 PM
Levine Zurit	SVP, Business Development	Apr 24 '26	Option Exercise	1.15	2,000	2,300	31,375	Apr 27 04:03 PM
Levine Zurit	SVP, Business Development	Apr 24 '26	Sale	3.20	2,000	6,400	29,375	Apr 27 04:03 PM
Ophir Eran	President and CEO	Apr 24 '26	Option Exercise	0.83	5,000	4,146	16,375	Apr 27 04:02 PM
Ophir Eran	President and CEO	Apr 24 '26	Sale	3.20	5,000	16,000	11,375	Apr 27 04:02 PM
Ophir Eran	Officer	Apr 24 '26	Proposed Sale	2.92	5,000	14,600		Apr 27 06:52 AM
Levine Zurit	Officer	Apr 24 '26	Proposed Sale	2.92	4,000	11,680		Apr 27 06:40 AM
Ophir Eran	President and CEO	Apr 14 '26	Option Exercise	0.83	5,000	4,146	16,375	Apr 15 04:10 PM
Ophir Eran	President and CEO	Apr 14 '26	Sale	2.90	5,000	14,521	11,375	Apr 15 04:10 PM
Levine Zurit	SVP, Business Development	Apr 14 '26	Option Exercise	1.15	2,000	2,300	31,375	Apr 15 04:07 PM
Levine Zurit	SVP, Business Development	Apr 14 '26	Sale	2.80	2,000	5,600	29,375	Apr 15 04:07 PM
Ophir Eran	Officer	Apr 14 '26	Proposed Sale	2.76	5,000	13,800		Apr 15 06:38 AM
Levine Zurit	Officer	Apr 14 '26	Proposed Sale	2.76	2,000	5,520		Apr 15 06:16 AM
Levine Zurit	SVP, Business Development	Apr 10 '26	Option Exercise	1.03	3,125	3,233	32,500	Apr 13 04:04 PM
Levine Zurit	SVP, Business Development	Apr 10 '26	Sale	2.56	3,125	8,012	29,375	Apr 13 04:04 PM
Levine Zurit	Officer	Apr 10 '26	Proposed Sale	2.48	2,000	4,960		Apr 13 07:28 AM
Levine Zurit	SVP, Business Development	Apr 08 '26	Option Exercise	0.89	5,375	4,778	34,750	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 07 '26	Option Exercise	0.83	2,500	2,073	31,875	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 08 '26	Sale	2.42	5,375	13,008	29,375	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 07 '26	Sale	2.30	2,500	5,750	29,375	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 01 '26	Option Exercise	0.92	3,500	3,223	32,875	Apr 03 07:31 AM
Levine Zurit	SVP, Business Development	Apr 01 '26	Sale	2.20	3,500	7,700	29,375	Apr 03 07:31 AM
Ophir Eran	President and CEO	Apr 01 '26	Option Exercise	0.83	5,625	4,664	17,000	Apr 03 07:29 AM
Ophir Eran	President and CEO	Apr 01 '26	Sale	2.21	5,625	12,413	11,375	Apr 03 07:29 AM
Ophir Eran	Officer	Apr 01 '26	Proposed Sale	2.13	5,625	11,981		Apr 02 10:06 AM
Levine Zurit	SVP, Business Development	Mar 26 '26	Option Exercise	0.83	11,875	9,847	41,250	Mar 30 06:04 PM
Levine Zurit	SVP, Business Development	Mar 26 '26	Sale	2.04	11,875	24,187	29,375	Mar 30 06:04 PM
Levine Zurit	Officer	Mar 26 '26	Proposed Sale	2.06	24,375	50,212		Mar 26 10:42 AM

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Executive ChairDr. Anat Cohen-Dayag Ph.D.

CEODr. Eran Ophir Ph.D.

Chief Operating OfficerDr. Pierre Ferre Ph.D.

Senior Vice President of Business DevelopmentDr. Zurit Levine Ph.D.

Chief Medical OfficerMs. Michelle Mahler M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEN

Compugen Ltd

Upgrade your Finviz experience